I 
115TH CONGRESS 
1ST SESSION 
H. R. 309 
To amend the Public Health Service Act to foster more effective implementa-
tion and coordination of clinical care for people with a complex metabolic 
or autoimmune disease, a disease resulting from insulin deficiency or 
insulin resistance, or complications caused by such a disease, and for 
other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JANUARY 5, 2017 
Mr. OLSON (for himself, Mr. LOEBSACK, Ms. DEGETTE, Ms. SINEMA, Mr. 
ZELDIN, Mr. DUNCAN of Tennessee, Mr. RYAN of Ohio, Mr. SERRANO, 
Mr. KING of New York, Mr. GUTHRIE, Mr. CUMMINGS, Mr. JOYCE of 
Ohio, Mr. DEUTCH, Mr. SESSIONS, Mrs. BLACKBURN, Mr. BUCSHON, 
Mr. BILIRAKIS, Mr. HENSARLING, and Mr. ALLEN) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce 
A BILL 
To amend the Public Health Service Act to foster more 
effective implementation and coordination of clinical care 
for people with a complex metabolic or autoimmune dis-
ease, a disease resulting from insulin deficiency or insulin 
resistance, or complications caused by such a disease, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
VerDate Sep 11 2014 
20:54 Jan 06, 2017
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H309.IH
H309
sradovich on DSK3GMQ082PROD with BILLS
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘National Clinical Care 
Commission Act’’. 
SEC. 2. ESTABLISHMENT OF A NATIONAL CLINICAL CARE 
COMMISSION. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.) is amended by adding at the end 
the following new section: 
‘‘SEC. 399V–7. NATIONAL CLINICAL CARE COMMISSION. 
‘‘(a) ESTABLISHMENT.—There is hereby established, 
within the Department of Health and Human Services, 
a National Clinical Care Commission (in this section re-
ferred to as the ‘Commission’) to evaluate, and rec-
ommend solutions regarding better coordination and 
leveraging of, programs within the Department and other 
Federal agencies that relate in any way to supporting ap-
propriate clinical care (such as any interactions between 
physicians and other health care providers and their pa-
tients related to treatment and care management) for indi-
viduals with— 
‘‘(1) one or more complex metabolic or auto-
immune diseases; 
‘‘(2) one or more diseases resulting from insulin 
deficiency or insulin resistance; or 
‘‘(3) complications caused by one or more of 
any of such diseases. 
VerDate Sep 11 2014 
20:54 Jan 06, 2017
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H309.IH
H309
sradovich on DSK3GMQ082PROD with BILLS
retary’s discretion, from among the heads (or 
their designees) of governmental or nongovern-
mental entities that impact clinical care of indi-
viduals with any of the diseases and complica-
tions described in subsection (a). 
‘‘(2) ADDITIONAL MEMBERS.—The Commission 
shall include additional voting members appointed by 
the Secretary, in consultation with national medical 
societies and patient advocacy organizations with ex-
pertise in the care and epidemiology of any of the 
diseases and complications described in subsection 
(a), including one or more such members from each 
of the following categories: 
‘‘(A) Clinical endocrinologists. 
‘‘(B) Physician specialties (other than as 
described in subparagraph (A)) that play a role 
in diseases and complications described in sub-
section (a), such as cardiologists, nephrologists, 
and eye care professionals. 
‘‘(C) Primary care physicians. 
‘‘(D) Non-physician health care profes-
sionals, such as certified diabetes educators, 
registered dieticians and nutrition professionals, 
nurses, nurse practitioners, physician assist-
ants. 
VerDate Sep 11 2014 
20:54 Jan 06, 2017
Jkt 069200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H309.IH
H309
sradovich on DSK3GMQ082PROD with BILLS
‘‘(E) Patient advocates. 
‘‘(F) National experts in the duties listed 
under subsection (c). 
‘‘(G) Health care providers furnishing 
services to a patient population that consists of 
a high percentage (as specified by the Sec-
retary) of individuals who are enrolled in a 
State plan under title XIX of the Social Secu-
rity Act or who are not covered under a health 
plan or health insurance coverage. 
‘‘(3) CHAIRPERSON.—The voting members of 
the Commission shall select a chairperson from the 
members appointed under paragraph (2) from the 
category under paragraph (2)(A). 
‘‘(4) MEETINGS.—The Commission shall meet 
at least twice, and not more than 4 times, a year. 
‘‘(5) BOARD TERMS.—Members of the Commis-
sion appointed pursuant to subparagraph (B) or (C) 
of paragraph (1), including the chairperson, shall 
serve for a 3-year term. A vacancy on the Commis-
sion shall be filled in the same manner as the origi-
nal appointments. 
‘‘(c) DUTIES.—The Commission shall— 
‘‘(1) evaluate programs of the Department of 
Health and Human Services regarding the utiliza-
VerDate Sep 11 2014 
20:54 Jan 06, 2017
Jkt 069200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H309.IH
H309
sradovich on DSK3GMQ082PROD with BILLS
tion of diabetes screening benefits, annual wellness 
visits, and other preventive health benefits that may 
reduce the incidence of the diseases and complica-
tions de scribed in subsection (a), including identi-
fying problems regarding such utilization and related 
data collection mechanisms and make recommenda-
tions; 
‘‘(2) identify current activities and critical gaps 
in Federal efforts to support clinicians in providing 
integrated, high-quality care to individuals with any 
of the diseases and complications described in sub-
section (a); 
‘‘(3) make recommendations regarding the co-
ordination of clinically based activities that are being 
supported by the Federal Government with respect 
to the diseases and complications described in sub-
section (a); 
‘‘(4) make recommendations regarding the de-
velopment and coordination of federally funded clin-
ical practice support tools for physicians and other 
health care professionals in caring for and managing 
the care of individuals with any of the diseases and 
complications described in subsection (a), specifically 
with regard to implementation of new treatments 
and technologies; 
VerDate Sep 11 2014 
20:54 Jan 06, 2017
Jkt 069200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H309.IH
H309
sradovich on DSK3GMQ082PROD with BILLS
‘‘(5) evaluate programs described in subsection 
(a) that are in existence as of the date of the enact-
ment of this section and determine if such programs 
are meeting the needs identified in paragraph (2) 
and, if such programs are determined as not meet-
ing such needs, recommend programs that would be 
more appropriate; 
‘‘(6) recommend, with respect to the diseases 
and complications described in subsection (a), clin-
ical pathways for new technologies and treatments, 
including future data collection activities, that may 
be developed and then used to evaluate— 
‘‘(A) various care models and methods; 
and 
‘‘(B) the impact of such models and meth-
ods on quality of care as measured by appro-
priate care parameters (such as A1C, blood 
pressure, and cholesterol levels); 
‘‘(7) evaluate and expand education and aware-
ness activities provided to physicians and other 
health care professionals regarding clinical practices 
for the prevention and treatment of the diseases and 
complications described in subsection (a); 
VerDate Sep 11 2014 
20:54 Jan 06, 2017
Jkt 069200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H309.IH
H309
sradovich on DSK3GMQ082PROD with BILLS
‘‘(8) review and recommend appropriate meth-
ods for outreach and dissemination of educational 
resources that— 
‘‘(A) address the diseases and complica-
tions described in subsection (a); 
‘‘(B) are funded by the Federal Govern-
ment; and 
‘‘(C) are intended for health care profes-
sionals and the public; and 
‘‘(9) carry out other activities, such as activities 
relating to the areas of public health and nutrition, 
that the Commission deems appropriate with respect 
to the diseases and complications described in sub-
section (a). 
‘‘(d) OPERATING PLAN.— 
‘‘(1) INITIAL PLAN.—Not later than 90 days 
after its first meeting, the Commission shall submit 
to the Secretary and the Congress an operating plan 
for carrying out the activities of the Commission as 
described in subsection (c). Such operating plan may 
include— 
‘‘(A) a list of specific activities that the 
Commission plans to conduct for purposes of 
carrying out the duties described in each of the 
paragraphs in subsection (c); 
VerDate Sep 11 2014 
20:54 Jan 06, 2017
Jkt 069200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H309.IH
H309
sradovich on DSK3GMQ082PROD with BILLS
‘‘(B) a plan for completing the activities; 
‘‘(C) a list of members of the Commission 
and other individuals who are not members of 
the Commission who will need to be involved to 
conduct such activities; 
‘‘(D) an explanation of Federal agency in-
volvement and coordination needed to conduct 
such activities; 
‘‘(E) a budget for conducting such activi-
ties; 
‘‘(F) a plan for evaluating the value and 
potential impact of the Commission’s work and 
recommendations, including the possible con-
tinuation of the Commission for the purposes of 
overseeing their implementation; and 
‘‘(G) other information that the Commis-
sion deems appropriate. 
‘‘(2) UPDATES.—The Commission shall periodi-
cally update the operating plan under paragraph (1) 
and submit such updates to the Secretary and the 
Congress. 
‘‘(e) FINAL REPORT.—By not later than 3 years after 
the date of the Commission’s first meeting, the Commis-
sion shall submit to the Secretary and the Congress a final 
report containing all of the findings and recommendations 
VerDate Sep 11 2014 
20:54 Jan 06, 2017
Jkt 069200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H309.IH
H309
sradovich on DSK3GMQ082PROD with BILLS
required by this section. Not later than 120 days after 
the submission of the final report, the Secretary shall re-
view the plan required by subsection (d)(1)(F) and submit 
to the Congress a recommendation on whether the Com-
mission should be reauthorized to operate after fiscal year 
2021. 
‘‘(f) SUNSET.—The Commission shall terminate 120 
days after submitting its final report, but not later than 
the end of fiscal year 2021.’’. 
Æ 
VerDate Sep 11 2014 
20:54 Jan 06, 2017
Jkt 069200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6301
E:\BILLS\H309.IH
H309
sradovich on DSK3GMQ082PROD with BILLS